<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
    xmlns:admin="http://webns.net/mvcb/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
	<channel>
<title>My RSS Feed</title><link>http://www.aldevron.com/index.php</link><description>Aldevron News</description><dc:language>en</dc:language><dc:creator>matt.chambers@aldevron.com</dc:creator><dc:rights>Copyright 2011 Aldevron</dc:rights><dc:date>2011-12-15T12:00:00-06:00</dc:date><admin:generatorAgent rdf:resource="http://www.realmacsoftware.com/" />
<admin:errorReportsTo rdf:resource="mailto:matt.chambers@aldevron.com" /><sy:updatePeriod>hourly</sy:updatePeriod>
<sy:updateFrequency>1</sy:updateFrequency>
<sy:updateBase>2000-01-01T12:00+00:00</sy:updateBase>
<lastBuildDate>Wed, 29 Jun 2011 15:38:09 -0500</lastBuildDate><item><title>Aldevron to generate antibodies for erythropoietin research consortium</title><dc:creator>matt.chambers@aldevron.com</dc:creator><category>PR</category><dc:date>2011-12-15T12:00:00-06:00</dc:date><link>http://www.aldevron.com/resources/press/files/erythropoietin2012.php#unique-entry-id-12</link><guid isPermaLink="true">http://www.aldevron.com/resources/press/files/erythropoietin2012.php#unique-entry-id-12</guid><content:encoded><![CDATA[Aldevron, a leader in the field of genetic immunisation, will apply its proprietary GENOVAC Antibody Technology to develop sets of monoclonal antibodies against the erythropoietin receptor (EpoR) for different applications, including antibodies capable of detecting EpoRs in its native conformation in tumour samples and the ability to modulate the function of this receptor.
]]></content:encoded></item><item><title>Genovac is now Aldevron Freiburg</title><dc:creator>matt.chambers@aldevron.com</dc:creator><category>PR</category><dc:date>2011-07-01T16:05:32-05:00</dc:date><link>http://www.aldevron.com/resources/press/files/Genovac_is_now_Aldevron.php#unique-entry-id-11</link><guid isPermaLink="true">http://www.aldevron.com/resources/press/files/Genovac_is_now_Aldevron.php#unique-entry-id-11</guid><content:encoded><![CDATA[This region includes Basel, Freiburg and Strasbourg, which apart from a concentration of large pharmaceutical companies (e.g., Novartis and Roche) all have well-known universities and research institutes (e.g., Friedrich Miescher Institute, Basel and Max-Planck Institute of Immunology in Freiburg)]]></content:encoded></item><item><title>Aldevron and Inserm co-develop a novel antibody-based approach for prevention and treatment of chronic hepatitis C</title><dc:creator>matt.chambers@aldevron.com</dc:creator><category>PR</category><dc:date>2010-09-10T13:53:17-05:00</dc:date><link>http://www.aldevron.com/resources/press/files/hepatitis_C_092010.php#unique-entry-id-10</link><guid isPermaLink="true">http://www.aldevron.com/resources/press/files/hepatitis_C_092010.php#unique-entry-id-10</guid><content:encoded><![CDATA[&ldquo;This approach clearly holds major promise for prevention of HCV infection in transplantation and widens the therapeutic arsenal against HCV infection&rdquo; says Thomas Baumert, Professor of Medicine at Inserm and principal investigator of the functional studies which is published in this month&rsquo;s issue of the journal Gastroenterology (Fofana I. et al 2010, Gastoenterology 139(3):953-964). ]]></content:encoded></item><item><title>Aldevron licenses HyperGRO&#x2122; DNA manufacturing technology from Nature Technology Corporation</title><dc:creator>matt.chambers@aldevron.com</dc:creator><category>PR</category><dc:date>2010-07-27T11:31:41-05:00</dc:date><link>http://www.aldevron.com/resources/press/files/dc931e0d84959cfc3a691c0df364480a-9.php#unique-entry-id-9</link><guid isPermaLink="true">http://www.aldevron.com/resources/press/files/dc931e0d84959cfc3a691c0df364480a-9.php#unique-entry-id-9</guid><content:encoded><![CDATA[By combining Aldevron&rsquo;s advances in biologics manufacturing and purification with NTC&rsquo;s HyperGRO&trade; processes, Aldevron continues to lead the industry as the vendor of choice for custom plasmid manufacture and high quality service.
]]></content:encoded></item><item><title>Aldevron could generate up to 20 jobs in Madison</title><dc:creator>matt.chambers@aldevron.com</dc:creator><category>Interest</category><dc:date>2009-10-23T11:21:16-05:00</dc:date><link>http://www.aldevron.com/resources/press/files/Madison_jobs_2009.php#unique-entry-id-8</link><guid isPermaLink="true">http://www.aldevron.com/resources/press/files/Madison_jobs_2009.php#unique-entry-id-8</guid><content:encoded><![CDATA[On becoming a part of Aldevron and looking forward to job growth, Tom Foti comments, &ldquo;The idea is to go from niche provider to a global contract service company that can offer a wide range of capabilities.&rdquo;  
]]></content:encoded></item><item><title>Aldevron Announces Expansion in Madison&#x2c; WI</title><dc:creator>matt.chambers@aldevron.com</dc:creator><category>PR</category><dc:date>2009-10-23T11:17:40-05:00</dc:date><link>http://www.aldevron.com/resources/press/files/madison_expansion.php#unique-entry-id-7</link><guid isPermaLink="true">http://www.aldevron.com/resources/press/files/madison_expansion.php#unique-entry-id-7</guid><content:encoded><![CDATA["I am working hard as Governor to build on Wisconsin's strengths in biotechnology, providing the resources and the infrastructure necessary for this industry to grow and prosper,&rdquo; Governor Doyle said. ]]></content:encoded></item><item><title>Aldevron manufacturing certified by CDC for select agents </title><dc:creator>matt.chambers@aldevron.com</dc:creator><category>PR</category><dc:date>2011-03-23T11:15:07-05:00</dc:date><link>http://www.aldevron.com/resources/press/files/CDC_certification.php#unique-entry-id-6</link><guid isPermaLink="true">http://www.aldevron.com/resources/press/files/CDC_certification.php#unique-entry-id-6</guid><content:encoded><![CDATA[Partially supported via a grant from the Therapeutic Discovery Project and a grant from Chemical Biological Medical Systems of the Department of Defense, Aldevron has applied their expertise in recombinant DNA technology to take the genes that code for the superantigen toxins and put it into non-pathogenic E.coli to produce the anti-cancer agents.  ]]></content:encoded></item><item><title>The Dakota Spirit</title><dc:creator>matt.chambers@aldevron.com</dc:creator><category>Interest</category><dc:date>2010-12-01T10:59:17-06:00</dc:date><link>http://www.aldevron.com/resources/press/files/dakota_spirit.php#unique-entry-id-5</link><guid isPermaLink="true">http://www.aldevron.com/resources/press/files/dakota_spirit.php#unique-entry-id-5</guid><content:encoded><![CDATA[In his modest Fargo office tucked inside a one-story building that bears more resemblance to a nondescript call center than it does to a state-of-the-art lab, Chambers believes the Dakota Spirit is spot-on when describing his own business philosophy: &ldquo;Farmers were the original entrepreneurs. ]]></content:encoded></item><item><title>Nature Technology Corporation and Aldevron to Manufacture First Genetic Cosmetic</title><dc:creator>matt.chambers@aldevron.com</dc:creator><category>PR</category><dc:date>2011-05-11T10:46:33-05:00</dc:date><link>http://www.aldevron.com/resources/press/files/gene_facelift_collaboration.php#unique-entry-id-4</link><guid isPermaLink="true">http://www.aldevron.com/resources/press/files/gene_facelift_collaboration.php#unique-entry-id-4</guid><content:encoded><![CDATA[Aaron Tabor, Gene Facelift, &ldquo;Our goal is to use the same gene transfer technology to help children battling inherited blistering skin disorders; patients with diabetic ulcers; paralyzed patients fighting pressure ulcers; and burn victims struggling to control infection and grow new skin."
]]></content:encoded></item><item><title>Aldevron winner of &#x201c;Best Places to Work in Industry&#x201d;</title><dc:creator>matt.chambers@aldevron.com</dc:creator><category>Interest</category><dc:date>2011-05-06T10:27:41-05:00</dc:date><link>http://www.aldevron.com/resources/press/files/best_places_to_work_2011.php#unique-entry-id-3</link><guid isPermaLink="true">http://www.aldevron.com/resources/press/files/best_places_to_work_2011.php#unique-entry-id-3</guid><content:encoded><![CDATA[We believe the survey results not only reflect the pride we take in making Aldevron a great place to work but also echo how that pride is conveyed in the quality of service we provide to our clients and collaborators.&rdquo;
]]></content:encoded></item></channel>
</rss>
